- Conditions
- Leukemia, Myelodysplastic Syndromes
- Interventions
- MGCD0103
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,777
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Myelodysplastic Syndrome, Acute Myeloid Leukemia
- Interventions
- Azacitidine, Rezatapopt
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Houston, Texas
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
- Interventions
- trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 459 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2013
- U.S. locations
- 2
- States / cities
- Duarte, California • Pasadena, California
- Conditions
- Myelodysplastic Syndromes
- Interventions
- PR1 leukemia peptide vaccine, incomplete Freund's adjuvant, sargramostim
- Biological
- Lead sponsor
- The Vaccine Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
- Interventions
- Azacitidine, Trametinib, Venetoclax
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Leukemia, Lung Cancer, Malignant Mesothelioma, Myelodysplastic Syndromes, Primary Peritoneal Cavity Cancer
- Interventions
- WT-1 analog peptide vaccine, incomplete Freund's adjuvant, sargramostim, polymerase chain reaction, flow cytometry, immunoenzyme technique
- Biological · Genetic · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Myelodysplastic Syndrome (MDS), Thrombocytopenia
- Interventions
- Eltrombopag
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myeloproliferative Neoplasms, Myelofibrosis, Myelodysplasia, Refractory Anemia, High Risk Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large Cell Non Hodgkins Lymphoma, Lymphoblastic Lymphoma, Burkitt Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult, Multiple Myeloma, Juvenile Myelomonocytic Leukemia, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, MRD Positive Leukemia, Natural Killer Cell Malignancies, Acquired Bone Marrow Failure Syndromes
- Interventions
- HSCT with TBI Regimen, HSCT with Non-TBI Regimen
- Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Essential Thrombocythemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis, Polycythemia Vera, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Interventions
- Carboplatin, Topotecan, Topotecan Hydrochloride, Veliparib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Newport Beach, California • Baltimore, Maryland + 2 more
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome
- Interventions
- dasatinib (SPRYCEL), all trans retinoic acid (VESANOID)
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Preleukemia, Myelodysplastic Syndromes, Refractory Acute Myeloid Leukemia
- Interventions
- BH-30236, Venetoclax
- Drug
- Lead sponsor
- BlossomHill Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 13
- States / cities
- Duarte, California • Los Angeles, California • Palo Alto, California + 10 more
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Interventions
- RO6870810
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Interventions
- CTX-712
- Drug
- Lead sponsor
- Chordia Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Chicago, Illinois + 5 more
- Conditions
- Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome
- Interventions
- RVU120(SEL120)
- Drug
- Lead sponsor
- Ryvu Therapeutics SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 5
- States / cities
- Miami, Florida • Atlanta, Georgia • St Louis, Missouri + 2 more
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Psychosocial Effects of Cancer and Its Treatment, Therapy-related Toxicity
- Interventions
- exercise intervention, telephone-based intervention, dietary intervention, educational intervention, questionnaire administration, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, assessment of therapy complications, peripheral blood stem cell transplantation, psychosocial assessment and care, quality-of-life assessment, standard follow-up care
- Behavioral · Dietary Supplement · Other + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- Ravulizumab, Eculizumab
- Biological
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Whittier, California • Fort Worth, Texas
- Conditions
- Adult Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Myeloid Leukemia
- Interventions
- 5-fluoro-2-deoxycytidine, tetrahydrouridine, laboratory biomarker analysis, reverse transcriptase-polymerase chain reaction, DNA methylation analysis
- Drug · Other · Genetic
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Leukemia
- Interventions
- Decitabine, Azacitidine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- MDS
- Interventions
- Lenalidomide and azacitidine combination
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Leukemia, Myelodysplastic Syndromes, Lymphoma, Multiple Myeloma, Hematologic Neoplasms
- Interventions
- BPX-501, Rimiducid
- Biological · Drug
- Lead sponsor
- Bellicum Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2033
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Westwood, Kansas • Buffalo, New York + 2 more
- Conditions
- Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Myeloproliferative Neoplasm
- Interventions
- Axatilimab, Azacitidine, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Survey Administration
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Uma Borate
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome
- Interventions
- Revlimid
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- etanercept, arsenic trioxide
- Biological · Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Myelodysplastic Syndrome, MDS, Trisomy 8
- Interventions
- rigosertib
- Drug
- Lead sponsor
- Traws Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Atlanta, Georgia • Rochester, Minnesota + 2 more